sorafenib has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
| Laufer, S; Pillaiyar, T | 1 |
| Ai, Y; Gong, N; Huang, Y; Ju, Z; Li, J; Lu, G; Wu, X; Wu, Y; Xiang, D; Yang, J; Yang, Z; Zeng, B | 1 |
1 review(s) available for sorafenib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |
2 other study(ies) available for sorafenib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
The impact of recent chemotherapy on immunity in 2 COVID-19 cases with gastrointestinal tumors: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Cyclobutanes; Docetaxel; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Organoplatinum Compounds; RNA, Viral; SARS-CoV-2; Sorafenib; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2021 |